What is Helix BioMedix, Inc. (HXBM) stock price today?

Helix BioMedix, Inc. (HXBM) is currently trading at $1.02, up 0% today.

What is HXBM P/E ratio?

Helix BioMedix, Inc.'s P/E ratio is -0.42. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is HXBM return on equity (ROE)?

Helix BioMedix, Inc.'s return on equity (ROE) is -30.45%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Helix BioMedix, Inc.'s market cap?

Helix BioMedix, Inc. has a market capitalization of $229202.

OTC · Biotechnology

Helix BioMedix, Inc. (HXBM) Stock

$1.02 +0.00% OTC: HXBM Healthcare

Helix BioMedix, Inc. is a biopharmaceutical company, which focuses on drug development for treatment of rare dermatological diseases, such as Xeroderma Pigmentosum.

Valuation

Metric	Value
Price	$1.02
Market Cap	$229202
P/E Ratio	-0.42
P/B Ratio	0.15
P/S Ratio	0.28
EPS (TTM)	$-2.45
52-Week High	$4.50
52-Week Low	$1.00
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-30.45%
ROA	-32.90%
ROCE	-38.72%
Gross Margin	99.36%
Operating Margin	-73.81%
Net Margin	-68.32%
Debt/Equity	0.00
Current Ratio	12.16

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$2.0M	$2.0M	$1.0M	$1.0M	$1.0M
Operating Profit	$-1.0M	$-1.0M	$-1.0M	$-1.0M	$-1.0M
Net Profit	$-1.0M	$-1.0M	$-1.0M	$-1.0M	$-1.0M
EPS	$-6.05	$-5.31	$-4.70	$-4.37	$-2.45
Op Margin	-55.8%	-61.5%	-98.6%	-132.3%	-73.8%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$5.0M	$4.0M	$3.0M	$2.0M	$2.0M
Total Liabilities	$0	$0	$0	$0	$0
Cash	$3.0M	$3.0M	$3.0M	$2.0M	$1.0M
Borrowings	$0	$0	$0	$0	$0

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-1.0M	$-1.0M	$-1.0M	—	$-1.0M
Investing Cash Flow	$0	$1.0M	$0	—	$0
Financing Cash Flow	$0	$0	$0	—	$0
Net Cash Flow	$-2.0M	$1.0M	$-1.0M	—	$-1.0M
Free Cash Flow	$-1.0M	$-1.0M	$-1.0M	$0	$-1.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	1.85
FCF Yield	-232.60%
Quick Ratio	12.16
Interest Coverage	0.00
Return 1Y	-77.00%
Return 3Y	-95.00%
Return 5Y	-95.36%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BPTHBio-Path Holdings, Inc.	$0.04	+0.00%	-0.05	$355002	0.00%
CNTRFCENTR Brands Corp.	$0.04	+0.00%	-1.92	$498471	0.00%
EMMAEmmaus Life Sciences, Inc.	$0.01	+0.09%	-0.09	$824010	0.00%
NGMCNext Generation Management Corp.	$0.10	+0.00%	0.00	$31163	0.00%
NSTMNovelStem International Corp.	$0.01	+30.00%	0.24	$641322	0.00%

About Helix BioMedix, Inc.

Helix BioMedix, Inc. is a biopharmaceutical company, which focuses on drug development for treatment of rare dermatological diseases, such as Xeroderma Pigmentosum. The company was founded in 1988 and is headquartered in Bothell, WA.

Helix BioMedix, Inc. is headquartered in US.

Helix BioMedix, Inc. (HXBM) stock trades at $1.02 with a market capitalization of $229202. The stock is valued at a price-to-earnings (P/E) ratio of -0.42, price-to-book of 0.15, price-to-sales of 0.28. Over the past 52 weeks the stock has ranged between $1.00 and $4.50, and currently trades 77.3% below its 52-week high.

On profitability, Helix BioMedix, Inc. generates a return on equity (ROE) of -30.45%, return on capital employed of -38.72%, an operating margin of -73.81%, a net profit margin of -68.32%.

Official website: www.helixbiomedix.com